Mankind Pharma Limited (BOM:543904)
India flag India · Delayed Price · Currency is INR
2,372.00
-13.00 (-0.55%)
At close: Aug 21, 2026

Mankind Pharma Balance Sheet

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
-3,9174,0743,8203,0483,025
Short-Term Investments
-2,7873,9807,4641,4131,023
Trading Asset Securities
-15,37316,90822,58110,7558,745
Cash & Short-Term Investments
22,07722,07724,96233,86515,21612,793
Cash Growth
-11.56%-11.56%-26.29%122.56%18.94%-36.18%
Accounts Receivable
-17,29515,3838,4835,7643,882
Other Receivables
-492.3363437.1321.02347.23
Receivables
-17,83115,7868,9496,1024,241
Inventory
-21,44520,93715,53514,98517,602
Prepaid Expenses
-515611.2603.9331.61,360
Other Current Assets
-7,6757,5876,7306,6458,072
Total Current Assets
-69,54269,88365,68243,27944,068
Property, Plant & Equipment
-36,14332,14031,38730,17023,896
Long-Term Investments
-4,5174,8483,1113,5782,404
Goodwill
-64,92664,926200.2200.23204.42
Other Intangible Assets
-96,411101,23616,63017,58418,742
Long-Term Deferred Tax Assets
-3,2471,079803.9297.77392.86
Other Long-Term Assets
-6,0093,4841,8182,0461,770
Total Assets
-280,795277,595119,63397,15491,477

Liabilities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
-13,41311,3347,77110,08210,764
Accrued Expenses
-8,5217,8125,4871,7102,598
Short-Term Debt
-8,21526,9571,5151,1508,052
Current Portion of Long-Term Debt
-25,6162,611196.9244.68242.47
Current Portion of Leases
-357.7143.934.225.5720.57
Current Income Taxes Payable
-109.1180.883.8462.56150.9
Current Unearned Revenue
-1,9221,9401,8591,6621,394
Other Current Liabilities
-6,9195,6564,2513,2943,013
Total Current Liabilities
-65,07356,63621,19718,63126,235
Long-Term Debt
-28,21255,262248.7231.47491.94
Long-Term Leases
-714.3140.377.151.7829.9
Long-Term Unearned Revenue
-299.4200229.6254.95201.54
Pension & Post-Retirement Benefits
-2,4871,5511,231978.89800.04
Long-Term Deferred Tax Liabilities
-18,40018,125890.7773.12556.21
Total Liabilities
-115,185131,91423,87520,92228,314

Shareholders' Equity

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
-412.8412.6400.6400.59400.59
Additional Paid-In Capital
-30,43230,075421.2421.17421.17
Retained Earnings
-140,420121,451101,56682,49969,729
Comprehensive Income & Other
--8,261-8,615-8,757-8,969-8,999
Total Common Equity
163,003163,003143,32493,63174,35261,552
Minority Interest
-2,6072,3582,1271,8811,611
Shareholders' Equity
165,611165,611145,68295,75876,23363,163
Total Liabilities & Equity
-280,795277,595119,63397,15491,477

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
63,11563,11585,1152,0721,7048,836
Net Cash (Debt)
-41,039-41,039-60,15331,79313,5123,957
Net Cash Growth
---135.29%241.51%-77.06%
Net Cash Per Share
-99.29-99.29-148.6379.2533.739.88
Filing Date Shares Outstanding
412.83412.83412.58400.64400.59400.59
Total Common Shares Outstanding
412.83412.83412.58400.59400.59400.59
Working Capital
-4,47013,24744,48524,64717,834
Book Value Per Share
394.85394.85347.39233.73185.61153.65
Tangible Book Value
1,6661,666-22,83876,80056,56842,606
Tangible Book Value Per Share
4.044.04-55.35191.72141.21106.36
Land
-3,8083,8013,5303,5282,435
Buildings
-10,62610,37312,48710,4605,863
Machinery
-26,29624,51321,50417,35213,921
Construction In Progress
-6,5483,0612,0714,9326,699
Leasehold Improvements
-136.7101.988.888.7464.47